- -

Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma

Mostrar el registro sencillo del ítem

Ficheros en el ítem

[Cerrado]
Nombre: Jantus - Complement ...
Tamaño: 434.4Kb
Formato: PDF
Descripción: Versión del Autor.
Solicitar una copia al autor
dc.contributor.author Ajona, D. es_ES
dc.contributor.author Pajares, M. J. es_ES
dc.contributor.author Chiara, M. D. es_ES
dc.contributor.author Rodrigo, J. P. es_ES
dc.contributor.author Jantus Lewintre, Eloisa es_ES
dc.contributor.author Camps, C. es_ES
dc.contributor.author Suarez, C. es_ES
dc.contributor.author Bagan, J. V. es_ES
dc.contributor.author Montuenga, L. M. es_ES
dc.contributor.author Pio, R. es_ES
dc.date.accessioned 2017-01-24T12:32:53Z
dc.date.available 2017-01-24T12:32:53Z
dc.date.issued 2015-10
dc.identifier.issn 1354-523X
dc.identifier.uri http://hdl.handle.net/10251/77266
dc.description.abstract OBJECTIVE: Complement C4d-containing fragments have been proposed as diagnostic markers for lung cancer. The purpose of this study was to evaluate the presence of C4d in oropharyngeal (OPSCC) and oral (OSCC) squamous cell carcinomas. SUBJECTS AND METHODS: C4d staining was analyzed by immunohistochemistry in 244 OPSCC surgical specimens. C4d levels were quantified by ELISA in resting saliva samples from 48 patients with oral leukoplakia and 62 with OSCC. Plasma samples from 21 patients with leukoplakia and 30 with oral carcinoma were also studied. RESULTS: C4d staining in OPSCC specimens was associated with nodal invasion (P = 0.001), histopathologic grade (P = 0.014), disease stage (P = 0.040), and focal-adhesion kinase expression (P < 0.001). No association was found between C4d and prognosis. Saliva C4d levels were higher in patients with oral cancer than in subjects with leukoplakia (0.07 +/- 0.07 vs 0.04 +/- 0.03 mu g ml(-1), P = 0.003). The area under the ROC curve was 0.63 (95%CI: 0.55-0.71). Salivary C4d levels in stage IV patients were higher than in patients with earlier stages (P = 0.028) and correlated with tumor size (P = 0.045). Plasma C4d levels also correlated with salivary C4d levels (P = 0.041), but differences between patients with oral cancer and subjects with leukoplakia were not significant (1.26 +/- 0.59 vs 1.09 +/- 0.39 mu g ml(-1), P = 0.232). CONCLUSION: C4d-containing fragments are detected in oral primary tumors and are increased in saliva from patients with OSCC. es_ES
dc.description.sponsorship We thank Amaya Lavin for technical assistance. This work was supported by Foundation for Applied Medical Research (FIMA), Red Tematica de Investigacion Cooperativa en Cancer (RD12/0036/0015, RD12/0036/0025, and RD12/0036/0040), and Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (FEDER, PI11/00618, PI13/00806, PI11/00929, and PI14/01686). en_EN
dc.language Inglés es_ES
dc.publisher Wiley es_ES
dc.relation.ispartof Oral Diseases es_ES
dc.rights Reserva de todos los derechos es_ES
dc.subject Head and neck cancer es_ES
dc.subject Head and neck cancer,squamous cell carcinoma,oral cancer,biomarker,diagnosis,complement system,C4d,saliva es_ES
dc.subject Squamous cell carcinoma es_ES
dc.subject Oral cancer es_ES
dc.subject Biomarker es_ES
dc.subject Diagnosis es_ES
dc.subject Complement system es_ES
dc.subject C4d es_ES
dc.subject Saliva es_ES
dc.subject.classification MICROBIOLOGIA es_ES
dc.title Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1111/odi.12363
dc.relation.projectID info:eu-repo/grantAgreement/MINECO//RD12%2F0036%2F0040/ES/Cáncer/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MICINN//PI11%2F00929/ES/Alteraciones genético-moleculares implicadas en el inicio y progresión de los tumores de cabeza y cuello y sus implicaciones clínicas/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MICINN//PI11%2F00618/ES/Papel del sistema del complemento en la progresión tumoral e identificación de marcadores moleculares relacionados su activación/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MINECO//RD12%2F0036%2F0015/ES/Cáncer/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MINECO//PI13%2F00806/ES/Herramientas moleculares para el análisis pronóstico y la identificación de nuevas dianas terapéuticas en carcinoma no microcítico de pulmón/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MINECO//RD12%2F0036%2F0025/ES/Cáncer/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MINECO//PI14%2F01686/ES/Identificación y validación de marcadores diagnósticos y dianas terapéuticas en cáncer de pulmón relacionados con la activación del sistema del complemento/ es_ES
dc.rights.accessRights Cerrado es_ES
dc.contributor.affiliation Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural es_ES
dc.description.bibliographicCitation Ajona, D.; Pajares, MJ.; Chiara, MD.; Rodrigo, JP.; Jantus Lewintre, E.; Camps, C.; Suarez, C.... (2015). Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. Oral Diseases. 21(7):899-904. doi:10.1111/odi.12363 es_ES
dc.description.accrualMethod S es_ES
dc.relation.publisherversion https://dx.doi.org/10.1111/odi.12363 es_ES
dc.description.upvformatpinicio 899 es_ES
dc.description.upvformatpfin 904 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 21 es_ES
dc.description.issue 7 es_ES
dc.relation.senia 301836 es_ES
dc.identifier.eissn 1601-0825
dc.contributor.funder Ministerio de Economía y Competitividad es_ES
dc.contributor.funder Fundación para la Investigación Médica Aplicada es_ES
dc.contributor.funder Ministerio de Ciencia e Innovación es_ES
dc.description.references Ajona, D., Pajares, M. J., Corrales, L., Perez-Gracia, J. L., Agorreta, J., Lozano, M. D., … Pio, R. (2013). Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. JNCI: Journal of the National Cancer Institute, 105(18), 1385-1393. doi:10.1093/jnci/djt205 es_ES
dc.description.references Ajona, D., Razquin, C., Pastor, M. D., Pajares, M. J., Garcia, J., Cardenal, F., … Pio, R. (2015). Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. PLOS ONE, 10(3), e0119878. doi:10.1371/journal.pone.0119878 es_ES
dc.description.references Arantes, L. M. R. B., de Carvalho, A. C., Melendez, M. E., Carvalho, A. L., & Goloni-Bertollo, E. M. (2014). Methylation as a biomarker for head and neck cancer. Oral Oncology, 50(6), 587-592. doi:10.1016/j.oraloncology.2014.02.015 es_ES
dc.description.references Bagan, J., Sarrion, G., & Jimenez, Y. (2010). Oral cancer: Clinical features. Oral Oncology, 46(6), 414-417. doi:10.1016/j.oraloncology.2010.03.009 es_ES
dc.description.references Bell, R. B., Kademani, D., Homer, L., Dierks, E. J., & Potter, B. E. (2007). Tongue Cancer: Is There a Difference in Survival Compared With Other Subsites in the Oral Cavity? Journal of Oral and Maxillofacial Surgery, 65(2), 229-236. doi:10.1016/j.joms.2005.11.094 es_ES
dc.description.references Bjørge, L., Hakulinen, J., Vintermyr, O. K., Jarva, H., Jensen, T. S., Iversen, O. E., & Meri, S. (2005). Ascitic complement system in ovarian cancer. British Journal of Cancer, 92(5), 895-905. doi:10.1038/sj.bjc.6602334 es_ES
dc.description.references Blom, A. M., Österborg, A., Mollnes, T. E., & Okroj, M. (2015). Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Molecular Immunology, 66(2), 164-170. doi:10.1016/j.molimm.2015.02.029 es_ES
dc.description.references Brailo, V., Vucicevic-Boras, V., Lukac, J., Biocina-Lukenda, D., Alajbeg-Zilic, I., Milenovic, A., & Balija, M. (2012). Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Medicina Oral Patología Oral y Cirugia Bucal, e10-e15. doi:10.4317/medoral.17323 es_ES
dc.description.references Canel, M. (2006). Overexpression of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma Is Independent of fak Gene Copy Number. Clinical Cancer Research, 12(11), 3272-3279. doi:10.1158/1078-0432.ccr-05-1583 es_ES
dc.description.references Canel, M., Secades, P., Garzón-Arango, M., Allonca, E., Suarez, C., Serrels, A., … Chiara, M.-D. (2008). Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. British Journal of Cancer, 98(7), 1274-1284. doi:10.1038/sj.bjc.6604286 es_ES
dc.description.references Cheng, Y.-S., Rees, T., & Wright, J. (2014). A review of research on salivary biomarkers for oral cancer detection. Clinical and Translational Medicine, 3(1), 3. doi:10.1186/2001-1326-3-3 es_ES
dc.description.references Corrales, L., Ajona, D., Rafail, S., Lasarte, J. J., Riezu-Boj, J. I., Lambris, J. D., … Pio, R. (2012). Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. The Journal of Immunology, 189(9), 4674-4683. doi:10.4049/jimmunol.1201654 es_ES
dc.description.references Franzmann, E. J., Reategui, E. P., Pedroso, F., Pernas, F. G., Karakullukcu, B. M., Carraway, K. L., … Goodwin, W. J. (2007). Soluble CD44 Is a Potential Marker for the Early Detection of Head and Neck Cancer. Cancer Epidemiology Biomarkers &amp; Prevention, 16(7), 1348-1355. doi:10.1158/1055-9965.epi-06-0011 es_ES
dc.description.references Hajishengallis, G. (2010). Complement and periodontitis. Biochemical Pharmacology, 80(12), 1992-2001. doi:10.1016/j.bcp.2010.06.017 es_ES
dc.description.references Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., … Stuart, J. M. (2014). Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 158(4), 929-944. doi:10.1016/j.cell.2014.06.049 es_ES
dc.description.references Hu, S., Arellano, M., Boontheung, P., Wang, J., Zhou, H., Jiang, J., … Wong, D. T. (2008). Salivary Proteomics for Oral Cancer Biomarker Discovery. Clinical Cancer Research, 14(19), 6246-6252. doi:10.1158/1078-0432.ccr-07-5037 es_ES
dc.description.references De Jong, E. P., Xie, H., Onsongo, G., Stone, M. D., Chen, X.-B., Kooren, J. A., … Griffin, T. J. (2010). Quantitative Proteomics Reveals Myosin and Actin as Promising Saliva Biomarkers for Distinguishing Pre-Malignant and Malignant Oral Lesions. PLoS ONE, 5(6), e11148. doi:10.1371/journal.pone.0011148 es_ES
dc.description.references Kesselring, R., Thiel, A., Pries, R., Fichtner-Feigl, S., Brunner, S., Seidel, P., … Wollenberg, B. (2014). The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack. European Journal of Cancer, 50(12), 2152-2161. doi:10.1016/j.ejca.2014.05.005 es_ES
dc.description.references Lingen, M. W. (2010). Screening for Oral Premalignancy and Cancer: What Platform and Which Biomarkers? Cancer Prevention Research, 3(9), 1056-1059. doi:10.1158/1940-6207.capr-10-0173 es_ES
dc.description.references Liu, C.-J., Lin, S.-C., Yang, C.-C., Cheng, H.-W., & Chang, K.-W. (2011). Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head & Neck, 34(2), 219-224. doi:10.1002/hed.21713 es_ES
dc.description.references Marimuthu, A., Chavan, S., Sathe, G., Sahasrabuddhe, N. A., Srikanth, S. M., Renuse, S., … Chatterjee, A. (2013). Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834(11), 2308-2316. doi:10.1016/j.bbapap.2013.04.029 es_ES
dc.description.references Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., … Lambris, J. D. (2008). Modulation of the antitumor immune response by complement. Nature Immunology, 9(11), 1225-1235. doi:10.1038/ni.1655 es_ES
dc.description.references McCormack, S. J., Brazinski, S. E., Jr, J. L. M., Werness, B. A., & Goldstein, D. J. (1997). Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene, 15(3), 265-274. doi:10.1038/sj.onc.1201186 es_ES
dc.description.references Menéndez, S. T., Rodrigo, J. P., Álvarez-Teijeiro, S., Villaronga, M. Á., Allonca, E., Vallina, A., … García-Pedrero, J. M. (2012). Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas. Modern Pathology, 25(8), 1069-1078. doi:10.1038/modpathol.2012.63 es_ES
dc.description.references Nitta, H., Wada, Y., Kawano, Y., Murakami, Y., Irie, A., Taniguchi, K., … Imamura, T. (2013). Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88). Clinical Cancer Research, 19(8), 2004-2013. doi:10.1158/1078-0432.ccr-12-1204 es_ES
dc.description.references NITTA, H., MURAKAMI, Y., WADA, Y., ETO, M., BABA, H., & IMAMURA, T. (2014). Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncology Reports, 32(4), 1715-1719. doi:10.3892/or.2014.3341 es_ES
dc.description.references Nunez-Cruz, S., Gimotty, P. A., Guerra, M. W., Connolly, D. C., Wu, Y.-Q., DeAngelis, R. A., … Scholler, N. (2012). Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. Neoplasia, 14(11), 994-IN1. doi:10.1593/neo.121262 es_ES
dc.description.references Pajares, M. J., Agorreta, J., Larrayoz, M., Vesin, A., Ezponda, T., Zudaire, I., … Montuenga, L. M. (2012). Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. Journal of Clinical Oncology, 30(10), 1129-1136. doi:10.1200/jco.2011.37.4231 es_ES
dc.description.references Pardoll, D. (2003). DOES THEIMMUNESYSTEMSEETUMORS ASFOREIGN ORSELF? Annual Review of Immunology, 21(1), 807-839. doi:10.1146/annurev.immunol.21.120601.141135 es_ES
dc.description.references Park, N. J., Zhou, H., Elashoff, D., Henson, B. S., Kastratovic, D. A., Abemayor, E., & Wong, D. T. (2009). Salivary microRNA: Discovery, Characterization, and Clinical Utility for Oral Cancer Detection. Clinical Cancer Research, 15(17), 5473-5477. doi:10.1158/1078-0432.ccr-09-0736 es_ES
dc.description.references Pio, R., Corrales, L., & Lambris, J. D. (2013). The Role of Complement in Tumor Growth. Tumor Microenvironment and Cellular Stress, 229-262. doi:10.1007/978-1-4614-5915-6_11 es_ES
dc.description.references Polanska, H., Raudenska, M., Gumulec, J., Sztalmachova, M., Adam, V., Kizek, R., & Masarik, M. (2014). Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncology, 50(3), 168-177. doi:10.1016/j.oraloncology.2013.12.008 es_ES
dc.description.references Prasad, G., & McCullough, M. (2013). Chemokines and Cytokines as Salivary Biomarkers for the Early Diagnosis of Oral Cancer. International Journal of Dentistry, 2013, 1-7. doi:10.1155/2013/813756 es_ES
dc.description.references Ravindranath, N. M. H., & Shuler, C. (2006). Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas. Journal of Oral Pathology and Medicine, 35(9), 560-567. doi:10.1111/j.1600-0714.2006.00466.x es_ES
dc.description.references Rhodus, N. L., Ho, V., Miller, C. S., Myers, S., & Ondrey, F. (2005). NF-κB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detection and Prevention, 29(1), 42-45. doi:10.1016/j.cdp.2004.10.003 es_ES
dc.description.references Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010). Complement: a key system for immune surveillance and homeostasis. Nature Immunology, 11(9), 785-797. doi:10.1038/ni.1923 es_ES
dc.description.references Rodrigo, J. P., Heideman, D. A. M., García-Pedrero, J. M., Fresno, M. F., Brakenhoff, R. H., Díaz Molina, J. P., … Hermsen, M. A. (2013). Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). International Journal of Cancer, 134(2), 487-492. doi:10.1002/ijc.28355 es_ES
dc.description.references Sainger, R. N. S., Shah, M. H., Desai, A. A., Shukla, S. N., Shah, P. M., Telang, S. D., & Patel, P. S. (2006). Clinical Significance of Serum p53 Antibodies in Oral Cancer. Tumori Journal, 92(2), 134-139. doi:10.1177/030089160609200209 es_ES
dc.description.references Vadrevu, S. K., Chintala, N. K., Sharma, S. K., Sharma, P., Cleveland, C., Riediger, L., … Markiewski, M. M. (2014). Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche. Cancer Research, 74(13), 3454-3465. doi:10.1158/0008-5472.can-14-0157 es_ES
dc.description.references Vaezi, A. E., Bepler, G., Bhagwat, N. R., Malysa, A., Rubatt, J. M., Chen, W., … Niedernhofer, L. J. (2014). Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. Cancer, 120(12), 1898-1907. doi:10.1002/cncr.28643 es_ES
dc.description.references Van der Waal, I. (2010). Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncology, 46(6), 423-425. doi:10.1016/j.oraloncology.2010.02.016 es_ES
dc.description.references Yang, Y., Chung, E. K., Zhou, B., Blanchong, C. A., Yu, C. Y., Füst, G., … Varga, L. (2003). Diversity in Intrinsic Strengths of the Human Complement System: Serum C4 Protein Concentrations Correlate with C4 Gene Size and Polygenic Variations, Hemolytic Activities, and Body Mass Index. The Journal of Immunology, 171(5), 2734-2745. doi:10.4049/jimmunol.171.5.2734 es_ES
dc.description.references Ytting, H., Jensenius, J. C., Christensen, I. J., Thiel, S., & Nielsen, H. J. (2004). Increased activity of the mannan‐binding lectin complement activation pathway in patients with colorectal cancer. Scandinavian Journal of Gastroenterology, 39(7), 674-679. doi:10.1080/00365520410005603 es_ES
dc.description.references Zimmermann, B. G., & Wong, D. T. (2008). Salivary mRNA targets for cancer diagnostics. Oral Oncology, 44(5), 425-429. doi:10.1016/j.oraloncology.2007.09.009 es_ES


Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem